LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease
NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients
Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
